Keep up-to-date with the latest access to medicines news and research, plus interviews and opinion from our partners and other experts, and videos and photo stories of our work.
News
-
A Tribute to Courage and Justice: Honoring Professor Hakima Himmich at the GSIPA2M 2025
With emotion palpable in the air, Moroccan journalist Amine Boushaba opened the tribute by recalling his personal journey as an...
-
Marrakech to Host Critical Global Summit on Intellectual Property and Access to Medicines — TRIPS@30: The Access Crisis
Organized by ITPC Global and the Make Medicines Affordable consortium, the summit takes place at a moment of historic urgency:...
-
An Earsplitting Silence: Pharma Makes Billions, Says Nothing About the Current Global Funding Crisis for HIV, Tuberculosis and Other Life-Threatening Illnesses
“It is shocking that the crisis facing the global HIV community has been met with such a resounding silence from...
-
‘A Matter of Life and Death’: Civil Society Groups Fight for Affordable DR-TB Treatment
“As the patent holder, Otsuka has prevented access to improved TB treatment due to its exorbitant prices. On World TB...
-
TNP+ is Successfully Opposing Big Pharma’s Hepatitis C Drug Monopoly
This win comes after years of campaigning by the AIDS Access Foundation (AAF) and the Thai Network of People Living...
-
Lenacapavir Patent Faces Opposition at the Eurasian Patent Office
“If Gilead Science’s patent application regarding Lenacapavir is granted, the patent will represent another significant barrier to the affordable access...
-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...
-
Empowering Africa’s Pharmaceutical Future: Local Manufacturing and IP Reform as Game-Changers
The African pharmaceutical market is on the rise, with its value soaring to $25 billion in 2022 and projected to...
-
ITPC-EECA Challenges Patents on core DR-TB Drug Pretomanid, Urging Eurasian Patent Office to Protect Access
According to WHO, 400,000 people developed DR-TB in 2023, yet only 44% (175, 923) of them were treated for it....
-
Ukrainian Patient Rights Group Opposes a Patent Applications on a Life-Saving HIV Drug
Rilpivirine, commonly known as RPV, is available in multiple formulations, including a daily oral medication, and in fixed-dose combination tablets,...
-
10th December Human Rights Day 2024: Achieving Equity in HIV Treatment and Prevention
On this Human Rights Day, the Global Network of People Living with HIV (GNP+) and the International Treatment Preparedness Coalition...
-
‘HIV Transmission Can be Stopped’: Leading HIV Researchers Make the Case for Compulsory Licensing of Lenacapavir
Lenacapavir (LEN), a groundbreaking, long-acting antiretroviral, has prevented nearly all HIV infections in clinical trials. LEN could be the answer...
